[1] V.G. Patel, W.K. Oh, M.D. Galsky, Treatment of muscle-invasive and advanced bladder cancer in 2020, CA: a cancer journal for clinicians, 70 (2020) 404-423.
[2] J. Kim, R. Akbani, C.J. Creighton, S.P. Lerner, J.N. Weinstein, G. Getz, D.J. Kwiatkowski, Invasive Bladder Cancer: Genomic Insights and Therapeutic Promise, Clin Cancer Res, 21 (2015) 4514-4524.
[3] G.Y. Liu, D.M. Sabatini, mTOR at the nexus of nutrition, growth, ageing and disease, Nature reviews. Molecular cell biology, 21 (2020) 183-203.
[4] M. Laplante, D.M. Sabatini, mTOR signaling in growth control and disease, Cell, 149 (2012) 274-293.
[5] Y.C. Kim, K.L. Guan, mTOR: a pharmacologic target for autophagy regulation, The Journal of clinical investigation, 125 (2015) 25-32.
[6] I. Ben-Sahra, B.D. Manning, mTORC1 signaling and the metabolic control of cell growth, Current opinion in cell biology, 45 (2017) 72-82.
[7] Y. Jiang, S. Su, Y. Zhang, J. Qian, P. Liu, Control of mTOR signaling by ubiquitin, Oncogene, 38 (2019) 3989-4001.
[8] J.H. Mao, I.J. Kim, D. Wu, J. Climent, H.C. Kang, R. DelRosario, A. Balmain, FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression, Science (New York, N.Y.), 321 (2008) 1499-1502.
[9] M. Tan, J. Xu, J. Siddiqui, F. Feng, Y. Sun, Depletion of SAG/RBX2 E3 ubiquitin ligase suppresses prostate tumorigenesis via inactivation of the PI3K/AKT/mTOR axis, Molecular cancer, 15 (2016) 81.
[10] L. Zhao, X. Wang, Y. Yu, L. Deng, L. Chen, X. Peng, C. Jiao, G. Gao, X. Tan, W. Pan, X. Ge, P. Wang, OTUB1 protein suppresses mTOR complex 1 (mTORC1) activity by deubiquitinating the mTORC1 inhibitor DEPTOR, The Journal of biological chemistry, 293 (2018) 4883-4892.
[11] P. Agrawal, Y.T. Chen, B. Schilling, B.W. Gibson, R.E. Hughes, Ubiquitin-specific peptidase 9, X-linked (USP9X) modulates activity of mammalian target of rapamycin (mTOR), The Journal of biological chemistry, 287 (2012) 21164-21175.
[12] N. Kayagaki, Q. Phung, S. Chan, R. Chaudhari, C. Quan, K.M. O'Rourke, M. Eby, E. Pietras, G. Cheng, J.F. Bazan, Z. Zhang, D. Arnott, V.M. Dixit, DUBA: a deubiquitinase that regulates type I interferon production, Science (New York, N.Y.), 318 (2007) 1628-1632.
[13] F. Li, Q. Sun, K. Liu, H. Han, N. Lin, Z. Cheng, Y. Cai, F. Tian, Z. Mao, T. Tong, W. Zhao, The deubiquitinase OTUD5 regulates Ku80 stability and non-homologous end joining, Cellular and molecular life sciences : CMLS, 76 (2019) 3861-3873.
[14] A. de Vivo, A. Sanchez, J. Yegres, J. Kim, S. Emly, Y. Kee, The OTUD5-UBR5 complex regulates FACT-mediated transcription at damaged chromatin, Nucleic acids research, 47 (2019) 729-746.
[15] Y. Guo, F. Jiang, L. Kong, H. Wu, H. Zhang, X. Chen, J. Zhao, B. Cai, Y. Li, C. Ma, F. Yi, L. Zhang, B. Liu, Y. Zheng, L. Zhang, C. Gao, OTUD5 promotes innate antiviral and antitumor immunity through deubiquitinating and stabilizing STING, Cellular & molecular immunology, (2020).
[16] R.L. Wolfson, L. Chantranupong, R.A. Saxton, K. Shen, S.M. Scaria, J.R. Cantor, D.M. Sabatini, Sestrin2 is a leucine sensor for the mTORC1 pathway, Science (New York, N.Y.), 351 (2016) 43-48.
[17] I. Ben-Sahra, B. Dirat, K. Laurent, A. Puissant, P. Auberger, A. Budanov, J.F. Tanti, F. Bost, Sestrin2 integrates Akt and mTOR signaling to protect cells against energetic stress-induced death, Cell death and differentiation, 20 (2013) 611-619.
[18] T.B. Lear, K.C. Lockwood, Y. Ouyang, J.W. Evankovich, M.B. Larsen, B. Lin, Y. Liu, B.B. Chen, The RING-type E3 ligase RNF186 ubiquitinates Sestrin-2 and thereby controls nutrient sensing, The Journal of biological chemistry, 294 (2019) 16527-16534.
[19] J.H. Cho, K. Kim, S.A. Kim, S. Park, B.O. Park, J.H. Kim, S.Y. Kim, M.J. Kwon, M.H. Han, S.B. Lee, B.C. Park, S.G. Park, J.H. Kim, S. Kim, Deubiquitinase OTUD5 is a positive regulator of mTORC1 and mTORC2 signaling pathways, Cell death and differentiation, 28 (2021) 900-914.
[20] H. Hua, Q. Kong, H. Zhang, J. Wang, T. Luo, Y. Jiang, Targeting mTOR for cancer therapy, Journal of hematology & oncology, 12 (2019) 71.
[21] U. Saran, M. Foti, J.F. Dufour, Cellular and molecular effects of the mTOR inhibitor everolimus, Clinical science (London, England : 1979), 129 (2015) 895-914.
[22] P.J. Houghton, Everolimus, Clin Cancer Res, 16 (2010) 1368-1372.
[23] J. Baselga, M. Campone, M. Piccart, H.A. Burris, 3rd, H.S. Rugo, T. Sahmoud, S. Noguchi, M. Gnant, K.I. Pritchard, F. Lebrun, J.T. Beck, Y. Ito, D. Yardley, I. Deleu, A. Perez, T. Bachelot, L. Vittori, Z. Xu, P. Mukhopadhyay, D. Lebwohl, G.N. Hortobagyi, Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer, The New England journal of medicine, 366 (2012) 520-529.
[24] S. Mabuchi, D.A. Altomare, M. Cheung, L. Zhang, P.I. Poulikakos, H.H. Hensley, R.J. Schilder, R.F. Ozols, J.R. Testa, RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model, Clin Cancer Res, 13 (2007) 4261-4270.
[25] I. Altomare, H. Hurwitz, Everolimus in colorectal cancer, Expert opinion on pharmacotherapy, 14 (2013) 505-513.
[26] T. Peng, Q.P. Dou, Everolimus Inhibits Growth of Gemcitabine-Resistant Pancreatic Cancer Cells via Induction of Caspase-Dependent Apoptosis and G(2) /M Arrest, J Cell Biochem, 118 (2017) 2722-2730.
[27] E. Chiong, I.L. Lee, A. Dadbin, A.L. Sabichi, L. Harris, D. Urbauer, D.J. McConkey, R.J. Dickstein, T. Cheng, H.B. Grossman, Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells, Clin Cancer Res, 17 (2011) 2863-2873.
[28] R.J. Motzer, B. Escudier, S. Oudard, T.E. Hutson, C. Porta, S. Bracarda, V. Grünwald, J.A. Thompson, R.A. Figlin, N. Hollaender, G. Urbanowitz, W.J. Berg, A. Kay, D. Lebwohl, A. Ravaud, Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial, Lancet (London, England), 372 (2008) 449-456.
[29] A.V. Budanov, M. Karin, p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling, Cell, 134 (2008) 451-460.
[30] P. Wang, Y. Wu, Y. Li, J. Zheng, J. Tang, A novel RING finger E3 ligase RNF186 regulate ER stress-mediated apoptosis through interaction with BNip1, Cell Signal, 25 (2013) 2320-2333.
[31] Y. Ji, X. Tu, X. Hu, Z. Wang, S. Gao, Q. Zhang, W. Zhang, H. Zhang, W. Chen, The role and mechanism of action of RNF186 in colorectal cancer through negative regulation of NF-κB, Cell Signal, 75 (2020) 109764.